ALK EML4-ALK Method of providing the information for selecting the drugs for treating EML4-ALK positive non-small-cell lung cancer resistant to ALK inhibitors

摘要

The present invention provides a biomarker for providing information on drug selection in the treatment of EML4-ALK-positive non-small cell lung cancer resistant to an ALK inhibitor, which comprises an EML4-ALK-positive non-small cell lung cancer Compositions and kits for detecting the level of expression of miR-34a and / or miR-449 to provide information on drug selection in the treatment of RTI ID = 0.0 miR-34a / RTI